Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kiley

Podiatrist Council Bluffs, IA Doctor of Podiatric Medicine

NPI 1699883009 CMS profile 167485

1260 Valley View Dr, Council Bluffs, IA 51503

Open in the dashboard

General payments

$11,728

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kiley of Council Bluffs, IA is reported in the CMS Open Payments database as having received $11,728 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,061 38
2024 General $3,083 32
2023 General $2,442 28
2022 General $1,426 27
2021 General $640 11
2020 General $285 9
2019 General $791 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kiley
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Jeffrey Kiley were reported at $3,061. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Jeffrey Kiley Podiatrist median Middle half National median
2019 $791 $196 $72–$601 $163
2020 $285 $118 $38–$335 $114
2021 $640 $169 $57–$573 $132
2022 $1,426 $220 $74–$782 $149
2023 $2,442 $208 $71–$635 $160
2024 $3,083 $237 $87–$681 $164
2025 $3,061 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $9,637 127 payments
  2. Conetic Solutions, Inc. $717 5 payments
  3. Organogenesis Inc. $489 12 payments
  4. Arthrex, Inc. $485 7 payments
  5. ConvaTec Inc. $174 4 payments
  6. Orthofix Medical, Inc. $59 1 payment
  7. Kerecis Limited $27 1 payment
  8. Treace Medical Concepts, Inc. $23 1 payment
  9. Heron Therapeutics, Inc. $21 1 payment
  10. Smith+Nephew, Inc. $21 1 payment
  11. Other $75 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,417 160 payments
  2. Travel and Lodging $2,311 5 payments
Products named General payments · program years 2019–2025
  1. ORTHOLOC 2 LAPIFUSE $2,501 38 payments
  2. VIAFLOW $2,272 32 payments
  3. PROSTEP $770 1 payment
  4. ORTHOLOC 3DI $747 1 payment
  5. AUGMENT INJECTABLE $562 7 payments
  6. TRAUMA $556 15 payments
  7. BIOSKIN $481 5 payments
  8. Puraply $320 8 payments
  9. ACTISHIELD CF $320 4 payments
  10. N/A $295 4 payments
  11. Other $2,332 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

229

Median for Podiatry: 160

Drug cost

$2,008

Median for Podiatry: $2,368

Branded share of claims

16.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 37 $1,024
Meloxicam Generic 78 $166
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $149
Methylprednisolone Generic 22 $144
Diclofenac Sodium Generic 13 $134
Cephalexin Generic 13 $121
Ibuprofen Generic 17 $99
Terbinafine Hcl Generic 11 $99
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$184,131

Of which drugs: $64,524

Medicare patients

626

Average age 76

Services billed

2,562

367 women, 259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 34%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 21%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 153 $114

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record